Global Health Economics Outcome Research, Seagen Inc., Bothell, WA 98021, USA.
RTI Health Solutions, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK.
Future Oncol. 2021 Nov;17(33):4635-4647. doi: 10.2217/fon-2021-0742. Epub 2021 Aug 31.
A systematic literature review and network meta-analysis of randomized controlled trials in patients receiving therapy for HER2+ unresectable/metastatic breast cancer after ≥1 HER2-directed therapy was conducted to compare progression-free survival (PFS) and overall survival (OS). Hazard ratios (HRs) and relative differences from fractional polynomials (FPs) for PFS and OS were assessed by Bayesian network meta-analyses. For PFS, surface under the cumulative rankogram (SUCRA) ranked tucatinib plus trastuzumab with capecitabine as highest in both HR and FP analyses, followed by T-DM1 monotherapy and neratinib plus capecitabine. For OS, SUCRA ranked tucatinib plus trastuzumab with capecitabine as highest in both HR and FP analyses, followed by pertuzumab plus trastuzumab with capecitabine and T-DM1 monotherapy, with similar scores. Tucatinib plus trastuzumab with capecitabine, and T-DM1 monotherapy, consistently showed improved PFS and OS versus lapatinib/trastuzumab plus capecitabine and non-targeted treatments.
对接受过≥1 种曲妥珠单抗靶向治疗的 HER2+不可切除/转移性乳腺癌患者的治疗进行了系统文献回顾和网络荟萃分析，以比较无进展生存期（PFS）和总生存期（OS）。采用贝叶斯网络荟萃分析评估 PFS 和 OS 的风险比（HR）和来自分数多项式（FP）的相对差异。对于 PFS，累积等级排序曲线下面积（SUCRA）排名曲妥珠单抗联合卡培他滨的 tucatinib 在 HR 和 FP 分析中均为最高，其次是 T-DM1 单药治疗和 neratinib 联合卡培他滨。对于 OS，曲妥珠单抗联合卡培他滨的 tucatinib 在 HR 和 FP 分析中均为最高，其次是曲妥珠单抗联合卡培他滨的 pertuzumab 和 T-DM1 单药治疗，得分相似。曲妥珠单抗联合卡培他滨的 tucatinib 和 T-DM1 单药治疗与 lapatinib/trastuzumab 联合卡培他滨和非靶向治疗相比，始终显示出改善的 PFS 和 OS。
Clin Adv Hematol Oncol. 2020-9
N Engl J Med. 2019-12-11
Int J Clin Pharmacol Ther. 2018-2
Biochem Biophys Rep. 2023-11-28
World J Clin Oncol. 2023-5-24
Zotero 插件